Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 541


SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders.

Kaiser A, Schmidt M, Huber O, Frietsch JJ, Scholl S, Heidel FH, Hochhaus A, Müller JP, Ernst T.

Leukemia. 2020 Mar 25. doi: 10.1038/s41375-020-0803-3. [Epub ahead of print]


A 19-year-old patient with atypical chronic myeloid leukemia.

Ernst P, Engmann B, Frietsch JJ, Schnetzke U, Scholl S, Theis B, Kreipe HH, Ernst T, Glaser A, Haferlach T, Koch T, Hochhaus A, Hilgendorf I.

Ann Hematol. 2020 Mar 19. doi: 10.1007/s00277-020-03992-w. [Epub ahead of print] No abstract available.


European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R.

Leukemia. 2020 Mar 3. doi: 10.1038/s41375-020-0776-2. [Epub ahead of print] Review.


Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry.

Birndt S, Schenk T, Heinevetter B, Brunkhorst FM, Maschmeyer G, Rothmann F, Weber T, Müller M, Panse J, Penack O, Schroers R, Braess J, Frickhofen N, Ehl S, Janka G, Lehmberg K, Pletz MW, Hochhaus A, Ernst T, La Rosée P.

J Cancer Res Clin Oncol. 2020 Apr;146(4):1065-1077. doi: 10.1007/s00432-020-03139-4. Epub 2020 Feb 20.


Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction between Breast Cancer and Chronic Myeloid Leukemia.

Butt E, Stempfle K, Lister L, Wolf F, Kraft M, Herrmann AB, Viciano CP, Weber C, Hochhaus A, Ernst T, Hoffmann C, Zernecke A, Frietsch JJ.

Cells. 2020 Feb 14;9(2). pii: E444. doi: 10.3390/cells9020444.


Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology.

Hoffmann K, Cazemier K, Baldow C, Schuster S, Kheifetz Y, Schirm S, Horn M, Ernst T, Volgmann C, Thiede C, Hochhaus A, Bornhäuser M, Suttorp M, Scholz M, Glauche I, Loeffler M, Roeder I.

BMC Med Inform Decis Mak. 2020 Feb 10;20(1):28. doi: 10.1186/s12911-020-1039-x.


Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation.

Metzgeroth G, Schwaab J, Naumann N, Jawhar M, Haferlach T, Fabarius A, Hochhaus A, Hofmann WK, Cross NCP, Reiter A.

Blood Adv. 2020 Feb 11;4(3):440-443. doi: 10.1182/bloodadvances.2019001111.


Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.

Herrmann AB, Müller ML, Orth MF, Müller JP, Zernecke A, Hochhaus A, Ernst T, Butt E, Frietsch JJ.

J Cell Mol Med. 2020 Mar;24(5):2942-2955. doi: 10.1111/jcmm.14910. Epub 2020 Jan 19.


Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.

Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, Martinelli G, Petrie K, Zelent A, Böhmer FD, Groth M, Ernst T, Heidel FH, Scholl S, Hochhaus A, Schenk T.

Leukemia. 2020 Jan 16. doi: 10.1038/s41375-020-0706-3. [Epub ahead of print]


Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia.

Schmidt T, Kharabi Masouleh B, Loges S, Cauwenberghs S, Fraisl P, Maes C, Jonckx B, De Keersmaecker K, Kleppe M, Tjwa M, Schenk T, Vinckier S, Fragoso R, De Mol M, Beel K, Dias S, Verfaillie C, Clark RE, Brümmendorf TH, Vandenberghe P, Rafii S, Holyoake T, Hochhaus A, Cools J, Karin M, Carmeliet G, Dewerchin M, Carmeliet P.

Cancer Cell. 2020 Jan 13;37(1):135-136. doi: 10.1016/j.ccell.2019.12.010. No abstract available.


Measuring Phagocytosis of Aspergillus fumigatus Conidia by Human Leukocytes using Flow Cytometry.

Hartung S, Rauh C, Böttcher S, Hoang MTN, Jahreis S, Rummler S, Hochhaus A, von Lilienfeld-Toal M.

J Vis Exp. 2019 Dec 7;(154). doi: 10.3791/60397.


Do persons with chronic myeloid leukaemia have normal or near normal survival?

Radivoyevitch T, Weaver D, Hobbs B, Maciejewski JP, Hehlmann R, Jiang Q, Hochhaus A, Gale RP.

Leukemia. 2020 Feb;34(2):333-335. doi: 10.1038/s41375-019-0699-y. Epub 2019 Dec 20. No abstract available.


Molecular-defined clonal evolution in patients with chronic myeloid leukemia who were exposed to ionizing radiation following the Chernobyl nuclear disaster.

Ernst T, Rinke J, Hagen J, Dmytrenko I, Hochhaus A, Dyagil I.

Leukemia. 2020 Feb;34(2):645-650. doi: 10.1038/s41375-019-0679-2. Epub 2019 Dec 13. No abstract available.


Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW.

N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.


Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).

Brioli A, Manz K, Pfirrmann M, Hänel M, Schwarzer AC, Prange-Krex G, Fabisch C, Knop S, Illmer T, Krammer-Steiner B, Hochhaus A, von Lilienfeld-Toal M, Mügge LO.

J Cancer Res Clin Oncol. 2020 Mar;146(3):749-759. doi: 10.1007/s00432-019-03101-z. Epub 2019 Dec 2.


Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.

Franke GN, Maier J, Wildenberger K, Cross M, Giles FJ, Müller MC, Hochhaus A, Niederwieser D, Lange T.

J Mol Diagn. 2020 Jan;22(1):81-89. doi: 10.1016/j.jmoldx.2019.08.007. Epub 2019 Oct 24.


The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.

Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, Martinelli G, Petrie K, Zelent A, Böhmer FD, Groth M, Ernst T, Heidel FH, Scholl S, Hochhaus A, Schenk T.

Leukemia. 2019 Nov;33(11):2628-2639. doi: 10.1038/s41375-019-0581-y. Epub 2019 Oct 1. Erratum in: Leukemia. 2020 Jan 16;:.


Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells.

Mihajlović J, Diehl LAM, Hochhaus A, Clement JH.

J Cancer Res Clin Oncol. 2019 Nov;145(11):2675-2687. doi: 10.1007/s00432-019-03026-7. Epub 2019 Sep 17.


Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma.

Sautter L, Hofheinz R, Tuettenberg J, Grimm M, Vajkoczy P, Groden C, Schmieder K, Hochhaus A, Wenz F, Giordano FA.

Oncology. 2020;98(1):16-22. doi: 10.1159/000502483. Epub 2019 Sep 12.


5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.

Gawlitza AL, Speith J, Rinke J, Sajzew R, Müller EK, Schäfer V, Hochhaus A, Ernst T.

J Cancer Res Clin Oncol. 2019 Nov;145(11):2835-2843. doi: 10.1007/s00432-019-03016-9. Epub 2019 Sep 10.


Supplemental Content

Loading ...
Support Center